Shine-On BioMedical ,Ltd. Overview
Get informed when a big investor buys or sells
+ Follow-37.76%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for 6926.TWO is -37.76%. That is below the Healthcare sector average of 13.1%. Investors often review this figure alongside Shine-On BioMedical ,Ltd.'s historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, 6926.TWO currently prints -37.76% for ROE, while the sector average sits near 13.1%. That is roughly 388.2% below the sector mean. Large gaps often invite a closer look at Shine-On BioMedical ,Ltd.'s growth, margins, and balance sheet.
Return on Equity shows how effectively Shine-On BioMedical ,Ltd. converts resources into returns. At -37.76%, 6926.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting 6926.TWO's ROE (-37.76%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Shine-On BioMedical ,Ltd.'s ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
